Navigation Links
AlphaVax Announces Nomination for 2012 Vaccine Industry Excellence Award
Date:3/20/2012

RESEARCH TRIANGLE PARK, N.C., March 20, 2012 /PRNewswire/ -- AlphaVax, Inc. ("AVX") is pleased to report that it has been selected as a corporate nominee for the 2012 Vaccine Industry Excellence Award as the Best Early-Stage Vaccine Biotech Company. The award will be announced during the World Vaccine Congress meeting in Washington, DC in April.

AVX is pleased to be both included in the list of finalists as deemed by the panel of judges as well as being recognized as a leader in the field. The Company's proprietary replicon technology has been tested in several clinical trials involving approximately 400 patients. In concert with the Duke University Medical Center in Durham, NC, AVX is awaiting the initiation of a Phase I trial in HER2+ breast cancer.

About AlphaVax
Based in Research Triangle Park, NC, AVX has developed a new generation of vaccine products for diseases that represent significant market opportunities based on its novel, proprietary vector platform technology. AlphaVax is at the forefront of a completely new class of potent biopharmaceutical products aimed to participate in this market with its viral vector technology that has the clear potential to redefine the traditional concept of vaccines. The AlphaVax proprietary viral vector gene expression system has the potential for developing a range of effective vaccines in both cancer and infectious disease.

AlphaVax is focusing the commercial potential of its alphavaccine system in cancer immunotherapy. The development of immunotherapeutic treatments for cancer is a rapidly growing area in which AlphaVax will be taking a lead position in developing new treatment modalities utilizing its proprietary technology.


'/>"/>
SOURCE AlphaVax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. CareFusion Announces 510(k) Clearance and U.S. Launch of New Advanced Electrodiagnostic System
2. GeoVax Announces Private Placement of $2.2 Million
3. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
4. Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications
5. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
6. Floridas Leading Fertility Center Announces Successful Baby Delivery via Egg Freezing
7. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
8. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
9. Proteonomix Announces a Private Placement of $3.8 Million
10. Updated: Life Technologies Announces Fourth Quarter and Fiscal Year 2011 Results
11. ARUP Laboratories Announces Creation of Business Innovations Division
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... ... the implantation and pregnancy rates in frozen and fresh in vitro fertilization ... progesterone and maternal age to IVF success. , After comparing the results from ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. spent ... entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, 2017 ... joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, Grossmont ...
(Date:10/9/2017)...  BioTech Holdings announced today identification and patenting ... stem cell therapy prevents limb loss in animal ... that treatment with ProCell resulted in more than ... to standard bone marrow stem cell administration.  Interestingly, ... of therapeutic effect.  ...
(Date:10/7/2017)... , ... October 06, 2017 ... ... experience providing advanced instruments and applications consulting for microscopy and surface analysis, ... in application consulting, Nanoscience Analytical offers a broad range of contract analysis ...
Breaking Biology Technology:
(Date:5/16/2017)... -- Veratad Technologies, LLC ( www.veratad.com ), an innovative and ... solutions, announced today they will participate as a sponsor ... May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions of ... digital world, defining identity is critical to nearly every ...
(Date:4/24/2017)... April 24, 2017 Janice Kephart ... with  Identity Strategy Partners, LLP (IdSP) , today ... without President Trump,s March 6, 2017 Executive ... , refugee vetting can be instilled with greater confidence, ... now, all refugee applications are suspended by until ...
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):